Bariatric News is teaming with Medtronic on this World Obesity Day on 4th March and asking you to join the global community to raise awareness on obesity as a chronic disease, its causes and consequences, and call for action for improved prevention and treatment.
Eiger BioPharmaceuticals has announced positive results from the Phase 2 PREVENT study of Avexitide in patients with severe Post-Bariatric Hypoglycaemia (PBH), the outcomes were published in Journal of Clinical Endocrinology & Metabolism (Craig, C.M. et al, 2021).
A second study of the injectable anti-obesity medication, semaglutide, has confirmed the large weight losses reported in a study earlier this month, establishing the reliability and robustness of this new drug.
W L Gore & Associates (Gore) has launched the GORE Synecor Intraperitoneal Biomaterial in Europe, the Middle East and South Africa. The device was designed to address unmet needs in complex hernia repair, providing rapid vascularity and permanent strength with a low profile for single, effective hernia repair. The GORE SYNECOR Intraperitoneal Biomaterial is conceived for ease of use during laparoscopic, robotic and open surgical procedures.
A research group from Mind, Brain and Behaviour Research Centre (CIMCYC) of the University of Granada (UGR) has been studying the issue of excess weight from a neuroscientific perspective for many years, to determine the precise role played by the brain.